Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis
| SVRA Stock | USD 3.36 0.20 5.62% |
About 61% of Savara's investor base is looking to short. The analysis of the overall investor sentiment regarding Savara Inc suggests that many traders are alarmed. The current market sentiment, together with Savara's historical and current headlines, can help investors time the market. In addition, many technical investors use Savara Inc stock news signals to limit their universe of possible portfolio assets.
Savara |
LANGHORNE, Pa., December 21, 2023--Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath, a new serum-based blood test that can be used by physicians in the U.S. to obtain a definitive diagnosis of aPAP, a rare autoimmune lung disease mediated by autoantibodies targeting GM-CSF. Autoimmune PAP accounts for approximately 90 percent of all patients with PAP and has an estimated diagnosed prevalence of s
Read at finance.yahoo.com
 |
Savara Fundamental Analysis
We analyze Savara's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Savara using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Savara based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Savara is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Savara Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Savara stock to make a market-neutral strategy. Peer analysis of Savara could also be used in its relative valuation, which is a method of valuing Savara by comparing valuation metrics with similar companies.
Peers
Savara Related Equities
| PTIX | Protagenic Therapeutics | 5.77 | ||||
| ACLX | Arcellx | 5.73 | ||||
| IKNA | Ikena Oncology | 1.80 | ||||
| FENC | Fennec Pharmaceuticals | 1.32 | ||||
| EWTX | Edgewise Therapeutics | 1.15 | ||||
| CRNX | Crinetics Pharmaceuticals | 0.97 | ||||
| XOMAO | XOMA | 0.40 | ||||
| XOMA | XOMA Corp | 0.47 | ||||
| KZR | Kezar Life | 0.86 | ||||
| AVTE | Aerovate Therapeutics | 1.14 | ||||
| GPCR | Structure Therapeutics | 1.30 | ||||
| RZLT | Rezolute | 1.39 | ||||
| RVMD | Revolution Medicines | 1.82 | ||||
| STOK | Stoke Therapeutics | 2.11 | ||||
| XLO | Xilio Development | 2.80 | ||||
| TRDA | Entrada Therapeutics | 2.97 | ||||
| DYN | Dyne Therapeutics | 3.04 | ||||
| ALXO | Alx Oncology | 4.43 | ||||
| TPST | Tempest Therapeutics | 4.49 | ||||
| SRRK | Scholar Rock | 5.26 | ||||
| TARA | Protara Therapeutics | 6.30 | ||||
| ANAB | AnaptysBio | 32.83 |
Complementary Tools for Savara Stock analysis
When running Savara's price analysis, check to measure Savara's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Savara is operating at the current time. Most of Savara's value examination focuses on studying past and present price action to predict the probability of Savara's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Savara's price. Additionally, you may evaluate how the addition of Savara to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |